The first drug for preventing the progress of Alzheimer's is approved with caution by the US authorities

Summary of the approval:

  • The US drug authority has approved Aduhelm using an accelerated approval pathway. 
  • Known to be the first drug that can prevent the progression of Alzheimer's disease.
  • A sigh of relief for over 50 million people who have dementia all over the world. 
  • The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need.
  • The clinical trials for Aduhelm were the first to show that a reduction in amyloid plaques—a hallmark finding in the brain of patients with Alzheimer's—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.
  • FDA requires the company to conduct a post-approval clinical trial to verify the drug's clinical benefit.
  • If the drug does not work as intended, the FDA can remove it from the market.

Leave a comment